Collaboration Agreement Signed: Caris Life Sciences has entered into a multi-year collaboration with Genentech, receiving an upfront payment of $25 million aimed at identifying and validating novel oncology targets in solid tumors, thereby advancing the development of precision medicine.
Significant Potential Earnings: Under the agreement, Caris is eligible for up to $1.1 billion in research, development, and commercial milestone payments, which will not only significantly enhance the company's financial strength but also accelerate its innovation capabilities in oncology treatment.
Leveraging Data Advantage: Caris utilizes insights from nearly 500,000 solid tumor samples along with comprehensive molecular and clinical data to offer flexible target discovery capabilities, combining tissue-based and data-centric techniques to drive the development of next-generation therapies, further solidifying its market position.
Optimistic Industry Outlook: This collaboration not only showcases Caris's leadership in precision medicine but also aligns with Roche's vision to develop first-in-class medicines for cancer patients with unmet needs, indicating substantial future market potential.
CAI
$26.655+Infinity%1D
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 40.40 USD with a low forecast of 38.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 40.40 USD with a low forecast of 38.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.700
Low
38.00
Averages
40.40
High
45.00
Current: 26.700
Low
38.00
Averages
40.40
High
45.00
Citi
Buy
upgrade
$34 -> $42
2025-08-13
Reason
Citi
Price Target
$34 -> $42
2025-08-13
upgrade
Buy
Reason
Citi raised the firm's price target on Caris Life Sciences to $42 from $34 and keeps a Buy rating on the shares. The firm views Caris Life's first quarter as a public company as strong and lifted estimates post the print.
BTIG
Mark Massaro
Buy
maintain
$38 -> $45
2025-08-13
Reason
BTIG
Mark Massaro
Price Target
$38 -> $45
2025-08-13
maintain
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Caris Life Sciences to $45 from $38 and keeps a Buy rating on the shares. The company reported a nearly unprecedented 31% revenue beat in its first quarter as a public company, driven primarily by higher-than-expected mix contribution from its MI Cancer Seek CDx, which carries a premium CMS rate of $8,455, the analyst tells investors in a research note. Caris seems to be holding firmly onto its market leadership in tissue therapy selection and estimates that the therapy selection market stands at just 30% overall penetration, the firm added.
JPMorgan
Rachel Vatnsdal
Overweight
initiated
$31
2025-07-14
Reason
JPMorgan
Rachel Vatnsdal
Price Target
$31
2025-07-14
initiated
Overweight
Reason
JPMorgan analyst Rachel Vatnsdal initiated coverage of Caris Life Sciences with an Overweight rating and $31 price target. The firm says Caris is a leading diagnostics company focused on enabling precision medicine. The company's whole exome sequencing and whole transcriptome sequencing technology targets significantly more genes than competitive assays, the analyst tells investors in a research note. JPMorgan believes Caris recently reached an inflection point with FDA approval of its tissue-based therapy selection assay.
Guggenheim
Buy
initiated
$32
2025-07-14
Reason
Guggenheim
Price Target
$32
2025-07-14
initiated
Buy
Reason
Guggenheim initiated coverage of Caris Life Sciences with a Buy rating and $32 price target. The firm says Caris is a precision diagnostics company offering clinical testing services in therapy selection indications and biopharma services through its assay menu and database. The company's therapy selection platform and large database will continue to be "important differentiations from competitors and to drive long-term growth," the analyst tells investors in a research note.
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
